Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-05-26
1995-12-26
Walsh, Stephen G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 424 941, A61K 3818, A61K 3843
Patent
active
054788048
ABSTRACT:
Conjugates comprising bFGF or other FGF polypeptides and a cytotoxic agent are prepared. The cytotoxic agent can be a ribosome-inactivating protein (RIP), such as saporin, which is attached to bFGF through a chemical bond, or the composition can be prepared as a recombinant DNA chimera. The conjugates are used to specifically target cells, in vivo and in vitro, which express FGF receptors. The cytotoxicity of the conjugates is proportional to the number of receptors expressed by a cell type. The conjugate is useful to effectively treat mammals, and in particular human patients, afflicted with tumorigenic conditions, such as human melanomas, human ovarian carcinomas, teratocarcinomas and neuroblastomas, and other FGF-mediated tumors caused by a proliferation of cells which express FGF receptors.
REFERENCES:
patent: 4468382 (1984-08-01), Bacha et al.
patent: 5084556 (1992-01-01), Brown
patent: 5087616 (1992-02-01), Myers et al.
patent: 5116753 (1992-05-01), Beattie et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5191067 (1993-03-01), Lappi et al.
patent: 5308622 (1994-05-01), Casscells et al.
Halaban et al, "BFGF is the Putative Natural Growth Factor for Human Melanocytes", In Vitro Cell & Devel. Biol. 23(1): 47-52. (Jan. 1987).
Imamura et al., "Purification of basic FGF receptors from rat brain," B.B.R.C., 155(2):583-590 (1988).
Huang and Huang, "Association of bovine brain-derived growth factor receptor with protein tyrosine kinase activity", J. Biol. Chem., 261:9568-9571 (1986).
Neufeld et al., "The identification and partial characterization of the fibroblast growth factor receptor of baby hamster kidney cells," J. Biol. Chem., 260:13860-13860 (1985).
Neufeld et al., "Basic and Acidic fibroblast growth factors interact with the same cell surface receptors," J. Biol. Chem., 261:5631-5637 (1986).
Blakey et al., "Comparison of the pharmacokinetics and hepototoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells," Cancer Research, 48:7072-7078 (1988).
Halaban et al., "bFGF as an autocrine growth factor for human melanomas," Oncogene Research, 3:177-186 (1988).
Baird et al., "Fibroblast growth factors" British Med. Bull., 45(2):438-452 (1989).
Barbieri et al., "Ribosome-inactivating proteins from plants: Properties and possible uses," Cancel Surveys, 1(3):489-520 (1982).
Beattie et al., "Selective elimination of fibroblasts from pancreatic islet monolayers by basic fibroblast growth factor-saporin mitotoxin," Diabetes, 39(8):1002-1005 (1990).
Bergamaschi et al., "Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6)," British J. Haematology, 68:379-384 (1988).
Grindey, G., "Current status of cancer drug development: Failure or limited success?" Cancer Cells, 2(6):163-171 (1990).
Lappi et al., "Mitotoxins: Growth factor-targeted cytotxic molecules," Progress in Growth Factor Research, 2:223-226 (1990).
Lappi et al., "Characterization of a Saponaria officinalis seed ribonsome-inactivating protein: Immunoreactivity and sequence homologies," Biochem. Biophys. Res.Comm., 129)3):934-942 (1985).
Lappi et al., "Biological and chemical characterization of basic FGF-saporin mitotoxin," Biochem. Biophys. Res. Comm., 160(2):917-923 (1989).
Lappi et al., "Basic fibroblast growth factor-saporin mitotoxin: An endothelial cell growth inhibitor," J. Cell. Biochem., Supp. 14E, UCLA Symposium on Molec. & Cell. Biol. Abstracts, 19th Annual Mtg., 31 Mar. to 22 Apr. 1990, N.Y., p. 222 (1990).
Montecucci et al., "N-terminal sequence of some ribosome-inactivating proteins," Int. J. Peptide Protein Res., 33:263-267 (1989).
Olwin et al., "Cell type and tissue distribution of the fibroblast growth factor receptor," J. Cell. Biochem., 39:443-454 (1989).
Soria, M., "Immunotoxins, ligand-toxin conjugates and molecular targeting," Pharm. Res., 21(2):35-46 (1989).
Stripe et al., "Ribosome-inactivating proteins from the seeds of Saponari a officinalis L. (soapwart), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree)," Biochem. J., 216:617-625 (1983).
Whalen et al., "The fate of intravenously administered bFGF and the effect of heparin," Growth Factors, 1:157-164 (1989).
Woodbury et al., "Identification of a cell surface protein, p. 97, in human melanomas and certain other neoplasms," Proc. Natl. Acad. Sci., 787(4):2183-2187 (1980).
Folkman et al., "Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor," Science 223:1296-1299(1984).
Moscatelli, D., "High and low affinity binding sites for basic fibroblast growth factor on cultured cells:Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells," J. Cell. Physio. 131:123-130 (1987).
Baird Andrew J.
Beitz Julie G.
Calabresi Paul
Clark Jeffrey W.
Frackelton, Jr. A. Raymond
Roger Williams General Hospital
The Salk Institute for Biological Studies
Walsh Stephen G.
LandOfFree
Treatment of tumorigenic pathophysiological conditions with FGF- does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of tumorigenic pathophysiological conditions with FGF-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of tumorigenic pathophysiological conditions with FGF- will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1369211